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AccuratemeasurementofplasmaHIV-1RNA levels (VL) is critical
for the optimal clinical management of HIV-1-infected patients.1
Several teams have reported VL underquantiﬁcations with recent
assays,2–7but anobjectiveassessmentof their frequency inunsorted
clinical cohorts with current commercial assays is needed. We
aimed todetermine the proportion of severe VLunderquantiﬁcation
(1 log 10 (copies/ml)) at the baseline evaluation of HIV-1 infection
in 99 patients with a newly-diagnosed infection in 2006, measured
by the gag-based Cobas TaqMan HIV-1 real-time (CTM) PCR assay
(Roche Diagnostics, Meylan, France) in comparison with the 50LTR-
based French Agence Nationale de Recherches sur le SIDA (ANRS)
Working Group for HIV Quantiﬁcation (AC11)/Biocentric Generic
HIV viral load assay (ANRS/Biocentric).5
Detection thresholds for the CTM and ANRS/Biocentric assays
were 1.6 and 2.5 log 10, respectively. In the case of VL difference
1.0 log 10, VL was retested using both assays on at least one later
plasma sample. When excluding samples with VL <2.5 log 10 in at
least one assay (26 samples), mean VL was 4.59  1.04 log 10 using
the CTM assay and 4.85  1.04 log 10 using the ANRS/Biocentric
assay. The mean ANRS/Biocentric-VL minus CTM-VL difference wasTable 1
Comparison of plasma HIV-1 RNA levels with the Cobas TaqMan HIV-1 real-time and
Cobas TaqMan HIV-1
real-time assay
ANRS/Biocentric assay
Copies/ml Log(copies/ml) Copies/ml Log(copies/m
Patient 1
1st plasma sample
(week 0)
459 2.7 207 600 5.3
2nd plasma sample
(week 10)
279 2.4 22 290 4.3
Patient 2
1st plasma sample
(week 0)
<40 <1.60 5000 3.7
2nd plasma sample
(week 8)
<40 <1.60 <300 <2.5
Patient 3
1st plasma sample
(week 0)
229 2.4 2297 3.4
2nd plasma sample
(week 5)
81 1.9 783 2.9
NC, not calculable.
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doi:10.1016/j.ijid.2009.11.0290.26  0.47 log 10. Three samples showed a difference 1 log 10
(Table 1). HIV-1/M pol subtype determination8 showed that HIV-1
was B in the ﬁrst case and CRF02-AG in the third case; PCR
ampliﬁcation was negative in the second case.
Our data, therefore, show that severe underquantiﬁcation of VL
using the CTM assay might in actuality affect 2–3% of patients at
the time of baseline assessment of their HIV-1 infection.
Interestingly, this proportion is in agreement with that estimated
in silico by Korn et al.,7 who recently reported VL underestimation
by >2 log 10 with the CTM assay and identiﬁed a mutation within
the downstream primer that might explain these impaired
quantiﬁcations: they found that about 2% of all HIV-1 group M
sequences in the Los Alamos HIV database had mutated nucleo-
tides at this position. In addition, in both our study and that of Korn
et al., B and non-B HIV-1/M subtypes were involved in cases of VL
underquantiﬁcation. These ﬁndings might suggest that VL should
be measured at least once at baseline evaluation of HIV-1 infection
using two different assays, and they emphasize the importance of
reports of impaired VL quantiﬁcation with commercialized assays
together with routine reactovigilance.2–7,9,10 These studies were
inﬂuential in leading Roche Diagnostics to modify their CTM assay
in 2009; the assay now targets both gag and LTR regions of the HIV-
1 genome.ANRS/Biocentric assays
Cobas TaqMan minus
ANRS/Biocentric
Level of
underestimation
by the Cobas
TaqMan HIV-1
real-time assay
HIV-1 group M subtype
l) Log(copies/ml) n-fold (copies/ml)
2.7 452 B
1.9 80
2.1 >125 PCR ampliﬁcation negative
in our genotyping assay
NC NC
1.0 10 CRF02-AG
1.0 10
ses. Published by Elsevier Ltd. All rights reserved.
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